Evidence map›Paper›PMID 34046535›Full record

ArticleCurrent opinion in biomedical engineering2018

Adeno-associated virus-mediated delivery of CRISPR-Cas9 for genome editing in the central nervous system.

Christina M Fuentes, David V Schaffer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current opinion in biomedical engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Viral Vectors for theFrontiers in bioengineering and biotechnology · 2022
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christina M FuentesDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.
David V SchafferDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.

Funding

Directed Evolution of Adeno-Associated Virus for Retinal Gene TherapyR01EY022975 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI FLANNERY, JOHN GERARD, SCHAFFER, DAVID V · 2014 to 2018
$2.1M
Stem Cell Engineering Training ProgramT32GM098218 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI HEALY, KEVIN EDWARD, SCHAFFER, DAVID V · 2011 to 2020
$1.8M
In Vivo Directed Evolution of Adeno-Associated Virus Vectors for Glioblastoma Multiforme Tumor-Initiating CellsR21EB021572 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI SCHAFFER, DAVID V · 2016 to 2017
$410k
NEI NIH HHS R01 EY022975NIBIB NIH HHS R21 EB021572NIGMS NIH HHS T32 GM098218
6 · The paper itself

Abstract

The emergence of CRISPR-Cas9 as a powerful genome editing tool has led to several studies exploring its potential to treat neurological disorders. Cas9 and its sgRNA can be readily engineered to target any gene and can be multiplexed to target several genes at once. Furthermore, the use of adeno-associated virus (AAV) to deliver with Cas9 and its sgRNA is a promising therapeutic combination with strong potential to reach the clinic. Here we discuss how Cas9 editing has been utilized for gene insertion, knockout, and deletion

Identifiers

PMID34046535
PMCPMC8153090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.